The clinical assesment of secondary AA amyloidosis assosciated with rheumatoid arthritis

The clinical assesment of secondary AA amyloidosis assosciated with rheumatoid arthritis - The clinical assesment of secondary AA amyloidosis assosciated with rheumatoid arthritis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003296

Enrollment

Registered

2010-03-06

Start date

2000-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis, AA amyloidosis

Interventions

Administration of immunosuppressive drugs for inflammatory response of rheumatoid arthritis as long as in the absence of adverse effect Administration of anti-hypertensive drugs for hypertension as lo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The enrolled patients have history of rheumatoid arthritis and has been diagnosed as systemic secondary AA amyloidosis by biopsy specimen.

Exclusion criteria

Exclusion criteria: These patients were excluded who has diabetic nephropathy or other proteinuric disease, and who does not have history of rheumatoid arthritis.

Design outcomes

Primary

Measure	Time frame
Improvement of organ dysfunctions and life prognosis	—

Countries

Japan

Contacts

Public ContactKazuhito Takeda

Aso Iizuka hospital The department of nephrology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026